A study in the Journal of the American Medical Association indicates that ubrogepant demonstrated greater rates of pain and symptom relief from migraine compared with a placebo. More than 20% of participants in a large-scale clinical trial reported being pain-free within 2 hours and more than 34% were relieved of the most severe symptoms associated with migraines when administered the drug, compared with 14% and 27%, respectively, from the placebo. These symptoms include light and noise sensitivity. Richard B. Lipton, MD, director of the Montefiore Headache Center in New York, who led the study, observes: “Migraine is the second leading cause of disability, and we need new acute treatments that are efficacious, safe, and tolerable.” Lipton is a consultant for Allergan, the pharmaceutical company that sponsored the trial. Ubrogepant is currently pending approval by the FDA. The drug targets a protein called calcitonin gene-related peptide, which is involved in the transmission of pain.

Read more here.

Pin It on Pinterest